Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.78 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2642014 | 0.99 | FGFR1 (0.76) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13304848 | 0.88 | FGFR1 (0.82) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2311242 | 0.88 | FGFR1 (1.00) | FGFR1ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL2647150 | 0.85 | FGFR1 (0.60) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2644383 | 0.84 | ALDH1A1 (0.67) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2642019 | 0.84 | FGFR1 (0.60) | FGFR1ALDH1A1SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL2641973 | 0.83 | ALDH1A1 (0.65) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4015486 | 0.83 | HTT (0.71) | FGFR1KDRMAPTHTT | |
| SCHEMBL27016387 | 0.82 | FGFR1 (0.58) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12135624 | 0.82 | KDR (0.76) | FGFR1KDRALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | claimed |
| EP-1361874-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2003-11-19 | — | — | EP | claimed |
| WO-2002064128-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2002-08-22 | — | — | WO | claimed |
| EP-0563001-A1 | Imidazole compounds, their preparation and use | NEUROSEARCH A/S (DK) | 1993-09-29 | — | — | EP | claimed |
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | disclosed |
| EP-1361874-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002064128-A1 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESSIVE OR INSUFFICIENT CELL DEATH | NEUROSEARCH A/S (DK) | 2002-08-22 | — | — | WO | disclosed |
| US-5360809-A | Imidazole compounds and their use as calcium channel blockers | NEUROSEARCH A/S (DK) | 1994-11-01 | — | — | US | disclosed |
| EP-0563001-A1 | Imidazole compounds, their preparation and use | NEUROSEARCH A/S (DK) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | APAF1, CASP9, AIFM1 | FGFR1 4070/4885KDR 4358/4885ALDH1A1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.